Cencora, Inc. $COR Shares Bought by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG raised its holdings in Cencora, Inc. (NYSE:CORFree Report) by 37.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 21,817 shares of the company’s stock after purchasing an additional 5,911 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Cencora were worth $7,373,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Legacy Capital Group California Inc. acquired a new stake in Cencora in the fourth quarter valued at approximately $207,000. Ayrshire Capital Management LLC grew its holdings in Cencora by 0.6% in the fourth quarter. Ayrshire Capital Management LLC now owns 20,430 shares of the company’s stock valued at $6,900,000 after purchasing an additional 122 shares during the period. Schear Investment Advisers LLC grew its holdings in Cencora by 3.7% in the fourth quarter. Schear Investment Advisers LLC now owns 6,774 shares of the company’s stock valued at $2,288,000 after purchasing an additional 242 shares during the period. Harbour Trust & Investment Management Co grew its holdings in Cencora by 4.1% in the fourth quarter. Harbour Trust & Investment Management Co now owns 15,043 shares of the company’s stock valued at $5,081,000 after purchasing an additional 588 shares during the period. Finally, Confluence Wealth Services Inc. acquired a new stake in Cencora in the fourth quarter valued at approximately $220,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on COR shares. Bank of America dropped their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Wells Fargo & Company raised their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. JPMorgan Chase & Co. raised their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Morgan Stanley set a $380.00 price target on Cencora in a research report on Tuesday, March 17th. Finally, Evercore set a $360.00 price target on Cencora in a research report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $398.17.

View Our Latest Report on Cencora

Cencora Trading Up 1.0%

Shares of COR opened at $311.29 on Friday. Cencora, Inc. has a 52-week low of $271.00 and a 52-week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm’s fifty day moving average is $338.39 and its two-hundred day moving average is $343.01. The stock has a market cap of $60.56 billion, a PE ratio of 37.42, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Cencora (NYSE:CORGet Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the previous year, the company posted $3.73 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. Research analysts forecast that Cencora, Inc. will post 17.57 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a dividend of $0.60 per share. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

See Also

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.